非小细胞肺癌患者新辅助免疫治疗后的辅助治疗
Adjuvant treatment after neoadjuvant immunotherapy in patients with non-small cell lung cancer.
作者信息
Zhao Junfeng, Li Ying, Li Ruyue, Yao Xiujing, Dong Xue, Su Lin, Li Yintao
机构信息
Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.
Department of Respiratory Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong 250000, China.
出版信息
iScience. 2024 Oct 28;27(12):111281. doi: 10.1016/j.isci.2024.111281. eCollection 2024 Dec 20.
This study explored the feasibility of adjuvant immunotherapy after NICT and surgery. A retrospective study was conducted on NSCLC patients who underwent NICT and surgery. Two patient groups were defined based on their adjuvant therapy after NICT and surgery: the Chemo group (chemotherapy alone) and the Immuno+Chemo group (chemotherapy combined with immunotherapy). Disease-free survival (DFS) and overall survival (OS) were also analyzed. In total, 209 patients were enrolled. The median DFS for the Immuno+Chemo group and the Chemo group was not reached vs. 26 months (hazard ratio [HR]: 0.498, 95% confidence interval [CI]: 0.315-0.787, = 0.002). A significant difference in OS was also observed; however, the median OS was not reached in either group (HR: 0.526, 95% CI: 0.287-0.965, = 0.034). Postoperative adjuvant chemotherapy combined with immunotherapy was significantly more effective than adjuvant chemotherapy alone in patients with NSCLC treated with NICT and surgery.
本研究探讨了新辅助诱导化疗（NICT）及手术后辅助免疫治疗的可行性。对接受NICT及手术的非小细胞肺癌（NSCLC）患者进行了一项回顾性研究。根据NICT及手术后的辅助治疗将患者分为两组：化疗组（单纯化疗）和免疫+化疗组（化疗联合免疫治疗）。还分析了无病生存期（DFS）和总生存期（OS）。总共纳入了209例患者。免疫+化疗组和化疗组的中位DFS未达到，而化疗组为26个月（风险比[HR]：0.498，95%置信区间[CI]：0.315-0.787，P = 0.002）。OS也观察到显著差异；然而，两组的中位OS均未达到（HR：0.526，95%CI：0.287-0.965，P = 0.034）。对于接受NICT及手术治疗的NSCLC患者，术后辅助化疗联合免疫治疗比单纯辅助化疗显著更有效。
Zotero 插件